[Amphotericin B deoxycholate (Fungizone): old drug, new versions].
Amphotericin B-deoxycholate (Fungizone) remains the main treatment of systemic mycoses. However, its toxicity, especially renal impairment, limits its use. The chemical properties of this molecule led to its association with lipidic structures. Among the three so-called liposomal formulations of amphotericin B, only one (AmBisome) is a true liposome. Its tolerance is good, along with high blood concentrations. The two others formulations, either in disk or ribbon form, are not true liposomes and these formulations are not as well tolerated as the former. These three forms of amphotericin are very expensive, thus limiting their use. The association of amphotericin B with other lipidic structures is of great interest. The direct solubilization of Fungizone in an emulsion (Intralipid 20%) is inexpensive and easily prepared extemporaneously; this preparation of Fungizone leads to a strong reduction of side effects and its efficacy is at least equivalent to conventional Fungizone. In the future, the association with triglycerides or lecithins is probable: possibly providing promising formulations.
Chavanet
P
P
Service des maladies infectieuses et tropicales, hôpital du Bocage, Dijon, France.
D000666:Amphotericin B; D000818:Animals; D000935:Antifungal Agents; D003840:Deoxycholic Acid; D004337:Drug Carriers; D004338:Drug Combinations; D006801:Humans; D008055:Lipids; D008081:Liposomes
D000935:Antifungal Agents; D004337:Drug Carriers; D004338:Drug Combinations; D008055:Lipids; D008081:Liposomes; D003840:Deoxycholic Acid; D000666:Amphotericin B
Amphotéricine B déoxycholate (Fungizone): vieux médicament, nouvelles versions.